Akari Therapeutics (AKTX) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
12 Nov, 2026Executive summary
Preclinical oncology developer focused on PH1 RNA-splicing-modulating ADCs; AKTX-101 is the lead program, with IND-enabling work aimed at Phase 1 readiness. No product revenue generated.
Initiated GLP toxicology studies for TROP2-targeted AKTX-101; a mid-2027 Phase 1 start is planned, subject to additional financing.
Q3 2026 net loss was $4.8 million versus $6.4 million a year earlier; nine-month net loss was $24.1 million versus $12.0 million, including $12.1 million of non-cash impairment charges.
Preclinical studies showed AKTX-101 activity in urothelial models with limited response or acquired resistance to approved ADCs.
Financial highlights
Q3 operating expenses were $4.7 million versus $7.4 million YoY; nine-month operating expenses were $25.0 million versus $14.0 million, primarily reflecting impairment charges.
Q3 R&D expense was $2.1 million versus $0.2 million; nine-month R&D was $5.6 million versus $1.7 million, mainly driven by ADC preclinical development.
Q3 G&A expense was $2.6 million versus $2.0 million; nine-month G&A was $7.3 million versus $7.1 million, including one-time prior placement-agent termination costs.
Operating cash use was $9.8 million for 9M 2026 versus $7.5 million; financing provided $10.4 million, and cash plus restricted cash ended the period at $5.8 million.
Outlook and guidance
IND-enabling nonclinical and CMC/manufacturing work, including GLP toxicology and GMP supply, continues toward a planned mid-2027 Phase 1 trial for AKTX-101.
Priorities include further resistance-model data, expanding partnerships, and progressing CEACAM5-targeted AKTX-102.
Existing cash was expected to fund operations into Q1 2027; additional capital is required, and financing availability, terms, and timing remain uncertain.
Future R&D spending depends on funding; potential sources include equity or debt, collaborations, preclinical or clinical funding arrangements, licensing, or asset transactions.
Latest events from Akari Therapeutics
- Vote proposed to increase shares for equity incentives; Board recommends approval.AKTX
Proxy filing - Q2 net loss was $4.8M; cash at $7.7M after $8.6M raise, more funding needed for trials.AKTX
Q2 2026 - Early-stage oncology firm advancing novel ADCs, facing high risk and reliant on future capital.AKTX
Registration filing - Resale registration covers nearly 6 million ADSs from private placements and warrants.AKTX
Registration filing - Novel ADC platform with immune-activating PH1 payload shows strong preclinical synergy with checkpoint inhibitors.AKTX
Webull Corporate Connect: Virtual Biotech Investment Webinar - Pre-revenue biotech registers resale of 5.99M ADSs; proceeds from warrants to fund R&D.AKTX
Registration filing - Preclinical oncology firm seeks up to $25M via ADS sales to fund R&D, with high dilution risk.AKTX
Registration filing - Comprehensive AGM proxy covers governance, compensation, and major share issuance proposals.AKTX
Proxy filing - Comprehensive AGM proxy covers governance, compensation, and major capital authorizations.AKTX
Proxy filing